Testing tafasitamab with lenalidomide for CNS lymphoma that has come back
Original title: Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early study in people, so it is still working out safety and how the drugs act.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether two drugs given together can help people whose lymphoma in the brain or spinal cord has returned.
Who this trial is for. This trial is for adults with central nervous system lymphoma that has come back after earlier treatment. It tests a drug called tafasitamab given together with a drug called lenalidomide.
Where it stands. This trial has not reported results. Everyone in it gets the same drug pair, and everyone knows which drugs they are getting. The study is looking at how this combination works in this type of lymphoma. It is also checking an idea the researchers want to test, that tafasitamab may make it easier for medicine to reach the brain. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If your lymphoma in the brain or spinal cord has come back, this is one study to know about. You could ask your care team whether it fits your situation and where the study is being run.
What it doesn't mean: This does not mean the drug pair works. A trial is a test, not a proven treatment. Joining a study is not a guarantee that it will help you. It is not a promise of a cure. The trial team decides who can take part.
Source: ClinicalTrials.gov, July 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.